Results 71 to 80 of about 4,697 (156)

In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib/acalabrutinib in chronic lymphocytic leukemia

Scientific Reports
Ibrutinib and acalabrutinib are first- and next-generation Bruton Tyrosine Kinase inhibitors (BTKi), respectively, approved for chronic lymphocytic leukemia (CLL).
Raúl Córdoba, Antoni Bayés-Genís, Ana Muntañola, Dolors Colomer, Jorge Castro, Carolina Leiva, Esther Álvarez, Eduardo Zatarain-Nicolas   +7 more
doaj   +1 more source

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma [PDF]

Zanubrutinib and acalabrutinib have demonstrated efficacy in separate single-arm clinical trials in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Shah, B., Ren, S., Srivastava, T., Yang, K., Xu, S., Saba, N.S., Gautam, R., Williams, R., Challagulla, S., Tam, C.S.   +9 more
core   +1 more source

Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy

Фармакоэкономика
Objective: to conduct a clinical and economic study of acalabrutinib for the treatment of adult patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy in the Russian Federation.Material and ...
S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

, 2023
ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia.
Woyach J. A., Ghia P., Seymour J. F., Kater A. P., Mato A., O'Brien S., Jurczak W., de Borja M., Bajwa N., Munir T., Byrd J. C., Furman R. R., Miranda P., Chanan-Khan A., Stilgenbauer S., Higgins K., Brown J. R., John E.   +17 more
core   +1 more source

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

Patient Preference and Adherence, 2023
Xiaoxiao Lu,1 Bruno Emond,2 Laura Morrison,2 Frederic Kinkead,2 Patrick Lefebvre,2 Marie-Hélène Lafeuille,2 Wasiulla Khan,1 Linda H Wu,1 Zaina P Qureshi,1 Ryan Jacobs3 1Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA,
Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Jacobs R   +9 more
doaj  

A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network

Pharmacology Research & Perspectives
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults, characterized by the accumulation of dysfunctional lymphocytes. Ibrutinib, a first‐generation Bruton tyrosine kinase (BTK) inhibitor, has significantly improved CLL ...
Abdulrahman Majrashi, Ying X. Gue, Alena Shantsila, Stella Williams, Catrin Tudur Smith, Gregory Y. H. Lip, Andrew R. Pettitt   +6 more
doaj   +1 more source

A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis

The Journal of Clinical Investigation, 2023
BACKGROUND IgE-mediated anaphylaxis is a potentially fatal systemic allergic reaction for which there are no currently FDA-approved preventative therapies.
Ragha V. Suresh, Collin Dunnam, Dhananjay Vaidya, Robert A. Wood, Bruce S. Bochner, Donald W. MacGlashan Jr., Melanie C. Dispenza   +6 more
doaj   +1 more source

Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

, 2021
Calquence® (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated ...
Molly S. Adam, Aaron M. Stewart, Jesus A. Rosales, David T. Vodak, Adam Smith, Michael M. Morgen, Deanna M. Mudie, Nishant Biswas, Christopher D. Craig   +8 more
core   +1 more source

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment

, 2022
Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
William Smith, Marbury, Thomas, Thomas Marbury, Vishwanathan, Karthick, Sharma, Shringi, Nguyen, Helen, Ware, Joseph A, Raquel Izumi, Xu, Yan, Smith, William, J. Greg Slatter, Kuo, Howard, Madere, Jeannine, Preston, Richard A., Slatter, J Greg, Yan Xu, Helen Nguyen, Anna Kwan, Kwan, Anna, Preston, Richard A, Podoll, Terry, Slatter, J. Greg, Jeannine Madere, Terry Podoll, Karthick Vishwanathan, Joseph A. Ware, Izumi, Raquel, Shringi Sharma, Ware, Joseph A., Howard Kuo, Richard A. Preston   +30 more
core   +1 more source

Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

, 2020
Background: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) often have a poor prognosis despite therapies using second-line chemoimmunotherapy. Achievement of CR with second-line therapy is associated with improved long-term
Fesler, Joanna, Hegerova, Livia, Batchelder, Ami, Pagel, John M, Egan, Daniel N, Bensinger, William, Holdread, Heather, Patel, Krish, Bailey, Megumi, Szeto, Jennie, Tsomo, Tenzin, Glennie, Sonia, Bailey, Neil, Mawad, Raya, Hall, Judson, Ferry, Joseph, Kane, David   +16 more
core   +1 more source